Results for tag: "Adcetris"

Adcetris (brentuximab vedotin) is a CD30-directed antibody-drug conjugate (ADC) used to treat certain types of Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). It is the first and only approved ADC for the treatment of HL and sALCL. Adcetris is a monoclonal antibody linked to a potent chemotherapy drug, monomethyl auristatin E (MMAE). The antibody binds to CD30, a protein found on the surface of HL and sALCL cells, and delivers the chemotherapy drug directly to the cancer cells. Adcetris is part of a larger market of leukemia drugs, which includes other ADCs, monoclonal antibodies, and chemotherapy drugs. These drugs are used to treat a variety of leukemias, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and acute lymphoblastic leukemia (ALL). Companies in the Adcetris market include Seattle Genetics, Takeda Pharmaceuticals, Pfizer, Novartis, and Celgene. Show Less Read more